UK pharmacies are welcoming the arrival of Wegovy, a once-daily weight-loss medicine that people have been anticipating for months. In coverage, the drug is described as an option aimed at helping with weight reduction, including for adults who experience ongoing difficulty losing weight. The article also discusses restrictions and concerns around eligibility, suggesting that some groups may face barriers to access the new formulation. While the piece emphasizes the potential benefits for midlife adults who have stubborn weight to lose, it does not provide detailed medical or regulatory guidance in the supplied text. Overall, the reporting focuses on the rollout and public interest in Wegovy’s availability in the UK, alongside questions about who is allowed to obtain it and why. The information presented centers on consumer-facing expectations and perceived health relevance, rather than on comparative effectiveness or specific clinical criteria. Further details on official prescribing rules and approved patient groups are not included in the text provided.